interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
NCT01774279 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 350
Last updated 2021-01-05
Summary
Anaplastic thyroid cancer has historically proven very difficult to research due to a combination of its rarity and the associated short survival period for those affected. In 2009, 2340 patients in the UK were diagnosed with thyroid cancer with 70-90 expected to be the anaplastic subtype 1,2. For these patients average life expectancy is in the range of 2-6 months with only a very small number surviving for more than one year. It is a highly aggressive form of cancer that is refractory to current treatment options. By collecting tissue and blood samples along with clinical data across the UK we will be able to accumulate numerically significant numbers of samples and data points which will facilitate research opportunities. Researchers will be encouraged to apply for access to the collected samples in order to try and establish the causal mechanisms for disease development, potential therapeutic targets and to relate clinical course and outcome with specific molecular defects. Due to the rarity it is not feasible for a single cancer centre or cancer network to accumulate sufficient samples for research in a meaningful timeframe hence the need for national collaboration in order to try and offer patients with this disease hope in the future.
All UK patients with anaplastic thyroid cancer would be potentially eligible. The project is expected to run for at least 15 years and all thyroid cancer clinicians will be encouraged to participate. Patients will be asked to donate surplus thyroid cancer tissue following routine biopsy procedures along with an optional blood sample.
2\. Objectives
Primary Objectives The primary objective of this project is to establish a national anaplastic thyroid cancer tissue collection to help facilitate both basic and translational research opportunities.
There is no direct research question that the project itself addresses at this stage. The research proposals that subsequently arise as a result of this project will be generated by accredited research parties from the UK and potentially internationally. These research proposals will be submitted to the interNational Anaplastic Thyroid Cancer Tissue Bank and Database Project (iNATT) Steering Committee for assessment. As the volume of material collected per patient is expected to be of small volume, by virtue of the specimen comprising core biopsy or fine needle aspirate material, research proposals will need to be prioritised according to the potential benefits the proposed research offers. Priority will be given to projects that may lead to the identification of potential therapeutic targets. Each research proposal will require their own ethical approval and research and development assessments before commencing.
The steering committee will be multidisciplinary and will include nationally respected researchers and thyroid cancer clinicians.
Scientific Justification The long term objective is to try and address the current lack of understanding about the aetiology and progression of this disease and ultimately to develop new therapeutic interventions that may slow the rate of disease progression, improve quality of life and prolong what is currently a very short survival.
Due to the short prognosis following diagnosis it is notoriously difficult to run interventional therapeutic clinical trials in this patient population. Patients usually present with locally advanced and metastatic disease and as a consequence are often of poor performance status making clinical trial participation very problematic. If potential therapeutic targets could be identified in vivo it would potentially open up new therapeutic avenues whilst sparing some patients with the 'wrong' molecular profile futile treatment.
This is a unique project within the setting of anaplastic thyroid cancer research.
Conditions
- Anaplastic Thyroid Cancer
Interventions
- OTHER
-
Tissue, blood and clinical data collection
Sponsors & Collaborators
-
Velindre NHS Trust
lead OTHER_GOV
Principal Investigators
-
Laura Moss, MB BCh · Velindre University NHS Trust
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2025-02-28
- Completion
- 2025-03-31
Countries
- Ireland
- United Kingdom
Study Locations
More Related Trials
-
International Cooperation for Post-Cherynobyl NIS Thyroid Tissue and Data Banks
NCT00339274 ·Status: COMPLETED
-
Assessment of Repeat Fine Needle Aspiration (FNA) to Detect Thyroid Cancer
NCT00954837 ·Status: WITHDRAWN ·Phase: NA
-
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
NCT05819593 ·Status: NOT_YET_RECRUITING
-
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
NCT01974284 ·Status: TERMINATED ·Phase: NA
-
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
NCT01460030 ·Status: COMPLETED ·Phase: PHASE3
-
To Perform a Post-market Study of the Performance of the Idylla ThyroidPrint Assay Using Clinical Samples in Predicting the Nature of Indeterminate Thyroid Nodules (ITNs) Across Multiple Centers.
NCT06849284 ·Status: RECRUITING
-
Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer
NCT03469544 ·Status: UNKNOWN
-
Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
NCT04411290 ·Status: UNKNOWN
-
Environmental Factors and Thyroid Cancer
NCT05172921 ·Status: RECRUITING
-
Thalidomide in Treating Patients With Thyroid Cancer
NCT00026533 ·Status: COMPLETED ·Phase: PHASE2
-
Review of Multimodality Management of Anaplastic Thyroid Cancer
NCT00280852 ·Status: COMPLETED
-
microRNA in Thyroid Cancer
NCT01964508 ·Status: COMPLETED
-
Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer
NCT05796258 ·Status: COMPLETED
-
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
NCT06073223 ·Status: COMPLETED ·Phase: NA
-
The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter
NCT01384786 ·Status: COMPLETED
-
Identification of Molecular Biomarkers for Thyroid Cancer
NCT04133870 ·Status: UNKNOWN
-
Assessment of CA 19-9 in Patients' With Thyroid Malignancies
NCT05124938 ·Status: UNKNOWN
-
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer
NCT04868045 ·Status: WITHDRAWN ·Phase: PHASE1
-
Thyroid Disease Serum Repository
NCT00592605 ·Status: COMPLETED
-
Post-radiation Hypothyroidism After IMRT for Nasopharyngeal Carcinoma
NCT02689609 ·Status: COMPLETED
-
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
NCT01730638 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma
NCT06268600 ·Status: RECRUITING ·Phase: NA
-
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
NCT04927416 ·Status: RECRUITING ·Phase: PHASE2
-
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
NCT01441154 ·Status: COMPLETED
-
Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer
NCT05275946 ·Status: COMPLETED ·Phase: PHASE1